Key result
Anticoagulation is recommended for all patients with hypertrophic cardiomyopathy who develop atrial fibrillation to mitigate their high risk of thromboembolic events.
Why the study?
Does anticoagulation reduce stroke and thromboembolic events in patients with hypertrophic cardiomyopathy and atrial fibrillation?
Does anticoagulation reduce stroke and thromboembolic events in patients with hypertrophic cardiomyopathy and atrial fibrillation?
This review reinforces that patients with hypertrophic cardiomyopathy who develop atrial fibrillation are at high risk for stroke and should receive universal anticoagulation therapy.
Supports anticoagulation in HCM with AF; leaves open need for randomized confirmation of net benefit.
Hypertrophic cardiomyopathy (HCM) represents a common inherited cardiac disorder with well-known complications Including stroke and sudden cardiac death. There is a recognised association between HCM and the development of AF. This review describes the epidemiology of AF within the HCM population and analyses the risk factors for the development of AF. It further discusses the outcomes associated with AF in this population, including the evidence in support of higher stroke risk in patients with HCM with AF compared with the general AF population. Finally, the evidence and recommendations for anticoagulation in this patient group are addressed.
No takes yet. Share an insight, caveat, or question.
Camm et al. (2017) conducted a review in Hypertrophic cardiomyopathy and atrial fibrillation. Anticoagulation was evaluated. Anticoagulation is recommended for all patients with hypertrophic cardiomyopathy who develop atrial fibrillation to mitigate their high risk of thromboembolic events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: